Surrozen Inc
SRZN23.000USD
+1.240+5.70%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
197.13MMarket Cap
LossP/E TTM
More Details of Surrozen Inc Company
Surrozen, Inc. is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.
Surrozen Inc Info
Ticker SymbolSRZN
Company nameSurrozen Inc
IPO dateNov 23, 2020
CEOParker (Craig C)
Number of employees40
Security typeOrdinary Share
Fiscal year-endNov 23
Address171 Oyster Point Blvd
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16504752820
Websitehttps://www.surrozen.com
Ticker SymbolSRZN
IPO dateNov 23, 2020
CEOParker (Craig C)
Company Executives of Surrozen Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Yang Li, Ph.D.
Mr. Yang Li, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
13.74K
+3.00%
Mr. Charles O. Williams
Mr. Charles O. Williams
Chief Operating Officer, Corporate Secretary
Chief Operating Officer, Corporate Secretary
9.38K
+4.45%
Dr. Mary Haak-Frendscho, Ph.D.
Dr. Mary Haak-Frendscho, Ph.D.
Independent Director
Independent Director
2.34K
--
Dr. Shao-Lee Lin, M.D., Ph.D.
Dr. Shao-Lee Lin, M.D., Ph.D.
Independent Director
Independent Director
2.34K
--
Dr. Anna Berkenblit, M.D.
Dr. Anna Berkenblit, M.D.
Independent Director
Independent Director
2.34K
--
Mr. Christopher Y. Chai
Mr. Christopher Y. Chai
Independent Director
Independent Director
2.34K
--
Dr. Mace Rothenberg, M.D.
Dr. Mace Rothenberg, M.D.
Independent Director
Independent Director
2.34K
--
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Independent Director
Independent Director
--
--
Dr. David J. Woodhouse, Ph.D.
Dr. David J. Woodhouse, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Craig C. Parker
Mr. Craig C. Parker
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Yang Li, Ph.D.
Mr. Yang Li, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
13.74K
+3.00%
Mr. Charles O. Williams
Mr. Charles O. Williams
Chief Operating Officer, Corporate Secretary
Chief Operating Officer, Corporate Secretary
9.38K
+4.45%
Dr. Mary Haak-Frendscho, Ph.D.
Dr. Mary Haak-Frendscho, Ph.D.
Independent Director
Independent Director
2.34K
--
Dr. Shao-Lee Lin, M.D., Ph.D.
Dr. Shao-Lee Lin, M.D., Ph.D.
Independent Director
Independent Director
2.34K
--
Dr. Anna Berkenblit, M.D.
Dr. Anna Berkenblit, M.D.
Independent Director
Independent Director
2.34K
--
Mr. Christopher Y. Chai
Mr. Christopher Y. Chai
Independent Director
Independent Director
2.34K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Column Group LP
21.60%
StemPoint Capital LP
8.32%
VR Adviser, LLC
7.38%
RA Capital Management, LP
7.03%
Millennium Management LLC
6.59%
Other
49.07%
Shareholders
Shareholders
Proportion
The Column Group LP
21.60%
StemPoint Capital LP
8.32%
VR Adviser, LLC
7.38%
RA Capital Management, LP
7.03%
Millennium Management LLC
6.59%
Other
49.07%
Shareholder Types
Shareholders
Proportion
Venture Capital
45.48%
Hedge Fund
17.56%
Investment Advisor
13.43%
Investment Advisor/Hedge Fund
4.36%
Corporation
3.57%
Endowment Fund
2.16%
Research Firm
1.33%
Individual Investor
0.57%
Other
11.53%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
52
6.16M
71.83%
+31.92K
2025Q2
62
5.88M
68.70%
+2.83M
2025Q1
63
5.89M
68.82%
+2.82M
2024Q4
60
2.77M
85.24%
-182.72K
2024Q3
64
2.45M
79.78%
-789.59K
2024Q2
65
2.67M
92.21%
-363.75K
2024Q1
62
1.51M
74.09%
-612.70K
2023Q4
67
1.55M
75.80%
-569.05K
2023Q3
69
1.40M
67.10%
-482.07K
2023Q2
98
1.37M
65.24%
-770.64K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Column Group LP
1.50M
17.5%
--
--
Jun 30, 2025
StemPoint Capital LP
686.54K
8.01%
+445.71K
+185.08%
Jun 30, 2025
VR Adviser, LLC
632.93K
7.39%
--
--
Jun 30, 2025
RA Capital Management, LP
602.63K
7.03%
-76.50K
-11.27%
Jun 30, 2025
5AM Ventures
310.00K
3.62%
--
--
Jun 30, 2025
Access Industries, Inc.
306.00K
3.57%
+306.00K
--
Mar 24, 2025
The Vanguard Group, Inc.
218.95K
2.55%
+150.92K
+221.86%
Jun 30, 2025
Vivo Capital, LLC
260.00K
3.03%
--
--
Jun 30, 2025
Stonepine Capital Management, LLC
306.03K
3.57%
+20.25K
+7.08%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 12, 2023
Merger
15→1
Dec 12, 2023
Merger
15→1
Dec 12, 2023
Merger
15→1
Dec 12, 2023
Merger
15→1
Date
Type
Ratio
Dec 12, 2023
Merger
15→1
Dec 12, 2023
Merger
15→1
Dec 12, 2023
Merger
15→1
Dec 12, 2023
Merger
15→1
FAQs
Who are the top five shareholders of Surrozen Inc?
The top five shareholders of Surrozen Inc are:
The Column Group LP holds 1.50M shares, accounting for 17.50% of the total shares.
StemPoint Capital LP holds 686.54K shares, accounting for 8.01% of the total shares.
VR Adviser, LLC holds 632.93K shares, accounting for 7.39% of the total shares.
RA Capital Management, LP holds 602.63K shares, accounting for 7.03% of the total shares.
5AM Ventures holds 310.00K shares, accounting for 3.62% of the total shares.
The Column Group LP holds 1.50M shares, accounting for 17.50% of the total shares.
StemPoint Capital LP holds 686.54K shares, accounting for 8.01% of the total shares.
VR Adviser, LLC holds 632.93K shares, accounting for 7.39% of the total shares.
RA Capital Management, LP holds 602.63K shares, accounting for 7.03% of the total shares.
5AM Ventures holds 310.00K shares, accounting for 3.62% of the total shares.
What are the top three shareholder types of Surrozen Inc?
The top three shareholder types of Surrozen Inc are:
The Column Group LP
StemPoint Capital LP
VR Adviser, LLC
The Column Group LP
StemPoint Capital LP
VR Adviser, LLC
How many institutions hold shares of Surrozen Inc (SRZN)?
As of 2025Q3, 52 institutions hold shares of Surrozen Inc, with a combined market value of approximately 6.16M, accounting for 71.83% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 3.13%.
What is the biggest source of revenue for Surrozen Inc?
In --, the -- business generated the highest revenue for Surrozen Inc, amounting to -- and accounting for --% of total revenue.
